



RESEARCH & DEVELOPMENT COMMITTEE

TERMS OF REFERENCE

27 OCTOBER 2023

1 INTRODUCTION

1.1 These terms of reference are the terms of reference (the “**Terms of Reference**”) of the Research & Development Committee (the “**Committee**”) of the board of directors (the “**Board**”) of argenx SE (the “**Company**”).

1.2 These Terms of Reference were adopted by the Board on 27 October 2023 and remain in full force and effect until amended or terminated (in whole or in part). These Terms of Reference supersede any and all previously existing terms of reference of the Committee.

2 GENERAL ROLE AND RESPONSIBILITIES

The Committee is responsible for advising the Board, undertaking preparatory work and preparing appropriate resolutions, with respect to the company’s research and development activities, including early stage and pre-clinical research and discovery activities, clinical development activities, and scientific collaborations.

3 SPECIFIC DUTIES AND RESPONSIBILITIES

The Committee shall generally support the Company’s innovation mission, and shall in any event have the following duties and responsibilities:

- (a) monitoring and overseeing the research and development goals, strategies and measures of the Company;
- (b) serving as a sounding board to the Company’s senior management team and senior scientific personnel on R&D related topics;
- (c) performing strategic reviews of the Company’s key research and development programs, including the outcomes of key clinical studies;

- (d) reviewing and discussing emerging scientific trends and activities critical to the success of research and development of the Company;
- (e) reviewing the Company’s clinical and preclinical product pipeline;
- (f) reporting to the board of directors on the outcome of the strategic reviews; and
- (g) supporting the attraction, retention and development of senior research and development personnel of the Company.

Environment, Social and Governance (“ESG”)

- (h) when reviewing proposals for preclinical experiments, help ensure the Company meets its commitment to ensuring animal testing is carried out only when necessary and when no alternative methods are reasonably available;
- (i) ensure that the Company has policies and procedures in place to support high standards of animal welfare, minimizing pain and distress to research animals;
- (j) ensure that with respect to the Company’s non-financial performance reporting, the Company transparently reports on animal testing practices;
- (k) when reviewing proposals for clinical experiments, help ensure the Company prioritizes safety, dignity, and rights of trial participants in its clinical trial protocols and that informed consent is obtained in a transparent and ethically sound manner;
- (l) advocate for the regular monitoring and reporting of any adverse events or concerns that arise during clinical trials;
- (m) promote transparency in R&D practices, ensuring that findings, both positive and negative, are reported accurately and openly; and



RESEARCH AND DEVELOPMENT COMMITTEE

TERMS OF REFERENCE

(n) review and comment on the Company's annual non-financial reporting on R&D related topics, including in any case those which are specifically within the scope of the Committee's areas of expertise, and make any recommendations to the Audit and Compliance Committee and/or the Board with respect to such proposed reporting.

attend all or part of any Committee meeting.

5.2 The Committee shall meet at least four times annually, and further as often as requested by the chairperson of the Committee or by the chairperson of the Board.

5.3 The Committee may invite to its meetings, or a part thereof, Board members, senior members of the management team and such other persons as the Committee deems appropriate in order to carry out its responsibilities.

5.4 Interactions of members of the Committee outside of formal meetings shall be reflected in the minutes of the next formal Committee meeting to the extent relevant, and in any case to the extent that these interactions have led to recommendations to the Committee and/or the Board.

4 COMPOSITION COMMITTEE

4.1 The Committee shall consist of at least three members. The Board shall appoint the members of the Committee.

4.2 The Committee may include external advisors who are not Non-Executive Directors of the Company, as long as a majority of the members of the Committee are Non-Executive Directors.

4.3 All members of the Committee shall have adequate industrial, academic and/or practical experience within biopharmaceutical research and/or development activities.

4.4 The Board shall appoint and dismiss the members of the Committee. The members of the Committee shall serve for such term or terms as the Board may determine or until their earlier resignation or death.

4.5 The chairperson of the Committee (the "**Chairperson**") shall be designated by the Board. The corporate secretary shall act as the secretary to the Committee.

4.6 Every Non-Executive Director shall have access to all books and records of the Committee.

6 AMENDMENT AND DEVIATIONS

The Board may amend these Terms of Reference and/or revoke any powers granted by it to the Committee. The Board may allow temporary deviations from these Terms of Reference.

5 MEETINGS OF THE COMMITTEE

5.1 The Chief Scientific Officer and the Chief Medical Officer shall attend the Committee meetings, unless the Committee determines otherwise. The Committee may also invite other individuals to